EVG - Evgen Pharma delighted with cash position after promising first half
(NewsDirect)
Evgen Pharma PLC (AIM:EVG) CEO Dr HuwJones and new CFO Toni Hanninen speak to Thomas Warner from Proactiveafter the clinical stage drug development company announced itsinterim results for the six months to 31 September 2023.
Dr Jones gives an overview of how Evgenhas been performing on the operational side, highlighting clinicalprogress, the successful receipt of some new grant funding as well aschanges to the board and to the executive team with the hiring of ToniHanninen in late summer.
Hanninen gives an overview of how Evgenperformed financial during the reporting period, noting that therewere no nasty surprises during the six months and that thecompany's cash runway of £3.7mln currently runs to the end of2024. He goes on to say that he is "very very delighted" withthe length of the runway given the financial challenges many ofEvgen's peers are currently facing.
ContactDetails
Proactive UK Ltd
+44 20 7989 0813
Copyright (c) 2023 TheNewswire - All rights reserved.